Targeting calcium cycling proteins in heart failure through gene transfer

Journal of Physiology

Volumn 546, Issue 1, 2003, Pages 49-61

  del Monte, Federica ^a   Hajjar, Roger J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); BETA 2 ADRENERGIC RECEPTOR; CALCIUM; CALCIUM BINDING PROTEIN; CALSEQUESTRIN; CYCLOPIAZONIC ACID; ION CHANNEL; PARVALBUMIN; PHOSPHOLAMBAN; PHOSPHOTRANSFERASE; SODIUM CALCIUM EXCHANGE PROTEIN; THAPSIGARGIN; ADENOVIRUS VECTOR; BETA ADRENERGIC RECEPTOR; HERPESVIRUS VECTOR; LENTIVIRUS VECTOR; PLASMID DNA; REGULATOR PROTEIN; SERCA2A PROTEIN; UNCLASSIFIED DRUG;

DNA VECTOR; DRUG MECHANISM; DRUG STRUCTURE; EXCITATION CONTRACTION COUPLING; GENE TARGETING; GENE TRANSFER; HEART CONTRACTION; HEART DISEASE; HEART EXCITATION; HEART FAILURE; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; ADENOVIRIDAE; AMPLICON; GENE INSERTION; LENTIVIRINAE; PROTEIN EXPRESSION;

EID: 0037236421     PISSN: 00223751     EISSN: None     Source Type: Journal    
DOI: 10.1113/jphysiol.2002.026732     Document Type: Review

References (106)

1. Akhter S.A., Skaer C.A., Kypson A.P., McDonald P.H., Peppel K.C., Glower D.D., Lefkowitz R.J. & Koch W.J. (1997). Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A 94, 12100-12105.
2. Arai M., Matsui H. & Periasamy M. (1994). Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 74, 555-564.
3. Askari A.T. & Penn M.S. (2002). Targeted gene therapy for the treatment of cardiac dysfunction. Semin Thorac Cardiovasc Surg 14, 167-177.
4. Bers D.M. (2002a). Calcium and cardiac rhythms: physiological and pathophysiological. Circ Res 90, 14-17.
5. Bers D.M. (2002b). Cardiac excitation-contraction coupling. Nature 415, 198-205.
6. Bers D.M. (2002c). Cardiac Na/Ca exchange function in rabbit, mouse and man: What's the difference? J Mol Cell Cardiol 34, 369-373.
7. Beuckelmann D.J., Nabauer M. & Erdmann E. (1992). Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85, 1046-1055.
8. Boeckstegers P., von Degenfeld G., Heinrich D., Hullin R., Kupatt C. & Franz W. (1999). Regional myocardial gene transfer using high efficiency with selective pressure-regulated retroinfusion of coronary veins. Circulation 100, 1-184.
9. Brillantes A.M., Allen P., Takahashi T., Izumo S. & Marks A.R. (1992). Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-stage heart failure caused by ischemic versus dilated cardiomyopathy. Circ Res 71, 18-26 [published erratum appears in Circ Res 71, 1538].
10. Brillantes A.M., Bezprozvannaya S. & Marks A.R. (1994). Developmental and tissue-specific regulation of rabbit skeletal and cardiac muscle calcium channels involved in excitation-contraction coupling. Circ Res 75, 503-510.
11. 2+ affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban. J Biol Chem 275, 12129-12135.
12. Carr A.N. Schmidt A.G. Suzuki Y. del Montel F. Sato Y. Lanner C. Breeden K., Jing S.L., Allen P.B., Greengard P., Yatani A., Hoit B.D., Grupp I.L., Hajjar R.J., Depaoli-Roach A.A. & Kranias E.G. (2002). Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 22, 4124-4135.
13. Cemazar M., Sersa G., Wilson J., Tozer G.M., Hart S.L., Grosel A. & Dachs G.U. (2002). Effective gene transfer to solid tumors using different nonviral gene delivery techniques: Electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther 9, 399-406.
14. 2+ sparks. Cell Calcium 20, 129-140.
15. Chu G., Lester J.W., Young K.B., Luo W., Zhai J. & Kranias E.G. (2000). A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists. J Biol Chem 275, 38938-38943.
16. Chu G., Li L., Sato Y., Harrer J.M., Kadambi V.J., Hoit B.D., Bers D.M. & Kranias E.G. (1998). Pentameric assembly of phospholamban facilitates inhibition of cardiac function in vivo. J Biol Chem 273, 33674-33680.
17. Cordier L., Gao G.P., Hack A.A., McNally E.M., Wilson J.M., Chirmule N. & Sweeney HL (2001). Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 12, 205-215.
18. Coutu P & Metzger JM (2002). Optimal range for parvalbumin as relaxing agent in adult cardiac myocytes: gene transfer and mathematical modeling. Biophys J 82, 2565-2579.
19. Davidoff AJ & Gwathmey JK (1994). Pathophysiology of cardiomyopathies: Part I. Animal models and humans. Curr Opin Cardiol 9, 357-368.
20. Davis AR, Wivel NA, Palladino JL, Tao L & Wilson JM (2001). Construction of adenoviral vectors. Mol Biotechnol 18, 63-70.
21. del Monte F, Butler K, Boecker W, Gwathmey JK & Hajjar RJ (2002a). Novel technique of aortic banding followed by gene transfer during hypertrophy and heart failure. Physiol Genomics 9, 49-56.
22. del Monte F, Harding SE, Dec GW, Gwathmey JK & Hajjar RJ (2002b). Targeting phospholamban by gene transfer in human heart failure. Circulation 105, 904-907.
23. del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, Gwathmey JK, Rosenzweig A & Hajjar RJ (1999). Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100, 2308-2311.
24. del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey JK, Lewandowski DE & Hajjar RJ (2001). Improvement in survival and cardiac metabolism following gene transfer of SERCA2a in a rat model of heart failure. Circulation 104, 1424-1429.
25. Desai KH, Schauble E, Luo W, Kranias E & Bernstein D (1999). Phospholamban deficiency does not compromise exercise capacity Am J Physiol 276, H1172-1177.
26. Donahue JK, Kikkawa K, Johns DC, Marban E & Lawrence JH (1997). Ultrarapid highly efficient viral gene transfer to the heart. Proc Natl Acad Sci U S A 94, 4664-4668.
27. Donahue JK, Kikkawa K, Thomas AD, Marban E & Lawrence JH (1998). Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Therapy 5, 630-634.
28. 2-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 101, 71-77.
29. Engelhardt S, Hein L, Wiesmann F & Lohse MJ (1999). Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 96, 7059-7064.
30. Force T, Hajjar R, del Monte F, Rosenzweig A & Choukroun G (1999). Signaling pathways mediating the response to hypertrophic stress in the heart. Gene Expr 7, 337-348.
31. Frank K & Kranias EG (2000). Phospholamban and cardiac contractility. Ann Med 32, 572-578.
32. Fromes Y, Salmon A, Wang X, Collin H, Rouche A, Hagege A, Schwartz K & Fiszman MY (1999). Gene delivery to the myocardium by intrapericardial injection. Gene Therapy 6, 683-688.
33. Fuchs S, Baffour R, Shou M, Stabile E, Singh S, Schwartz B, Branellec D, Epstein SE & Kornowski R (2001). Could plasmid-mediated gene transfer into the myocardium be augmented by left ventricular guided laser myocardial injury? Catheter Cardiovasc Interv 54, 533-538.
34. Gao G, Qu G, Burnham MS, Huang J, Chirmule N, Joshi B, Yu QC, Marsh JA, Conceicao CM & Wilson JM (2000a). Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther 11, 2079-2091.
35. Gao GP, Wilson JM & Wivel NA (2000b). Production of recombinant adeno-associated virus. Adv Virus Res 55, 529-543.
36. Goins WF, Krisky DM, Wolfe DP, Fink DJ & Glorioso JC (2002). Development of replication-defective herpes simplex virus vectors. Methods Mol Med 69, 481-507.
37. Gomez AM, Valdivia HH, Cheng H, Lederer MR, Santana LF, Cannell MB, McCune SA, Altschuld RA & Lederer WJ (1997). Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 276, 800-806.
38. Greene AL, Lalli MJ, Ji Y, Babu GJ, Grupp I, Sussman M & Periasamy M (2000). Overexpression of SERCA2b in the heart leads to an increase in sarcoplasmic reticulum calcium transport function and increased cardiac contractility. J Biol Chem 275, 24722-24727.
39. Gruver EJ, Glass MG, Marsh JD & Gwathmey JK (1993). An animal model of dilated cardiomyopathy: characterization of dihydropyridine receptors and contractile performance. Am J Physiol 265, H1704-1711.
40. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE & Finkel T (1993). Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res 73, 1202-1207.
41. Gwathmey JK, Bentivegna LA, Ransil BJ, Grossman W & Morgan JP (1993). Relationship of abnormal intracellular calcium mobilisation to myocyte hypertrophy in human ventricular myocardium. Cardiovasc Res 27,199-203.
42. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W & Morgan JP (1987). Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 61, 70-76.
43. 2+. Circulation 82, 1266-1278.
44. Gwathmey JK & Morgan JP (1985). Altered calcium handling in experimental pressure-overload hypertrophy in the ferret. Circ Res 57, 836-843.
45. Gwathmey JK, Slawsky MT, Hajjar RJ, Briggs GM & Morgan JP (1990). Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest 85, 1599-1613.
46. Hajjar RJ, del Monte F, Matsui T & Rosenzweig A (2000a). Prospects for gene therapy for heart failure. Circ Res 86, 616-621.
47. Hajjar RJ, Kang JX, Gwathmey JK & Rosenzweig A (1997a). Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation 95, 423-429.
48. 2+ ATPase. Circ Res 81, 145-153.
49. Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK, Dec GW, Semigran MJ & Rosenzweig A (1998). Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci U S A 95, 5251-5256.
50. Hajjar RJ, Schwinger RH, Schmidt U, Kim CS, Lebeche D, Doye AA & Gwathmey JK (2000b). Myofilament calcium regulation in human myocardium. Circulation 101, 1679-1685.
51. Hasenfuss G, Holubarsch C, Hermann HP, Astheimer K, Pieske B & Just H (1994a). Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J 15, 164-170.
52. Hasenfuss G, Pieske B, Holubarsch C, Alpert NR & Just H (1993). Excitation-contraction coupling and contractile protein function in failing and nonfailing human myocardium. Adv Exp Med Biol 346, 91-100.
53. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 75, 434-442.
54. Hasenfuss G, Reinecke H, Studer R, Pieske B, Meyer M, Drexler H & Just H (1996). Calcium cycling proteins and force-frequency relationship in heart failure. Basic Res Cardiol 91, suppl. 2, 17-22.
55. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 99, 641-648.
56. 2+-ATPase activity and cardiac myocyte contractility. Circulation 100, 974-980.
57. Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y, Iwatate M, Li M, Wang L, Wilson JM, Wang Y, Ross J Jr & Chien KR (2002). Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8, 864-871.
58. Ikeda Y, Gu Y, Iwanaga Y, Hoshijima M, Oh SS, Giordano FJ, Chen J, Nigro V, Peterson KL, Chien KR & Ross J Jr (2002). Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer. Circulation 105, 502-508.
59. Isner JM (2002). Myocardial gene therapy. Nature 415, 234-239.
60. Izu LT, Wier WG & Balke CW (2001). Evolution of cardiac calcium waves from stochastic calcium sparks. Biophys 180, 103-20.
61. Johnson RG Jr & Kranias EG (1998). Cardiac sarcoplasmic reticulum function and regulation of contractility. Introduction. Ann N Y Acad Sci 853, xi-xvi.
62. Kadambi VJ & Kranias EG (1998). Genetically engineered mice: model systems for left ventricular failure. J Card Fail 4, 349-361.
63. Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW II, Walsh RA & Kranias EG (1996). Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 97, 533-539.
64. Koss KL & Kranias EG (1996). Phospholamban: A prominent regulator of myocardial contractility. Circ Res 79, 1059-1063.
65. Lai NC, Roth DM, Gao MH, Fine S, Head BP, Zhu J, McKirnan MD, Kwong C, Dalton N, Urasawa K, Roth DA & Hammond HK (2000). Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation 102, 2396-2401.
66. Li L, Desantiago J, Chu G, Kranias EG & Bers DM (2000). Phosphorylation of phospholamban and troponin I in beta-adrenergic- induced acceleration of cardiac relaxation. Am J Physiol 278, H769-779.
67. Li Y, Kranias EG, Mignery GA & Bers DM (2002). Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res 90, 309-316.
68. Logeart D, Hatem SN, Rucker-Martin C, Chossat N, Nevo N, Haddada H, Heimburger M, Perricaudet M & Mercadier JJ (2000). Highly efficient adenovirus-mediated gene transfer to cardiac myocytes after single-pass coronary delivery. Hum Gene Ther 11, 1015-1022.
69. 2+ ATPase isoforms and their role in muscle physiology and pathology. Ann N Y Acad Sci 853, 251-259.
70. Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doetschman T & Kranias EG (1994). Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res 75, 401-409.
71. 2+-content in isolated rat and rabbit myocardium. J Mol Cell Cardiol 32, 2249-2258.
72. Marban E (2002). Cardiac channelopathies. Nature 415, 213-218.
73. Marks AR (1997). Intracellular calcium-release channels: regulators of cell life and death. Am J Physiol 272, H597-605.
74. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N & Marks AR (2000). PKA phosphorylation dissociates FKBP126 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365-376.
75. Maurice JP, Hata JA, Shah AS, White DC, McDonald PH, Dolber PC, Wilson KH, Lefkowitz RJ, Glower DD & Koch WJ (1999). Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest 104, 21-29.
76. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR & Chien KR (1999). Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99, 313-322.
77. Miyamoto MI, del Monte F, Schmidt U, Matsui T, Guerrero JL, Gwathmey JK, Rosenzweig A & Hajjar RJ (2000). Adenoviral gene transfer of SERCA2a improves left ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A 97, 793-798.
78. Ng P, Beauchamp C, Evelegh C, Parks R & Graham FL (2001). Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol Ther 3, 809-815.
79. Ng P, Evelegh C, Cummings D & Graham FL (2002). Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system. J Virol 76, 4181-4189.
80. Ng P, Parks RJ, Cummings DT, Evelegh CM, Sankar U & Graham FL (1999). A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther 10, 2667-2672.
81. 2+ content in isolated failing and nonfailing human myocardium. Circ Res 85, 38-46.
82. 2+ exchanger expression and function in an arrhythmogenic rabbit model of heart failure. Circ Res 85, 1009-1019.
83. Pogwizd SM, Schlotthauer K, Li L, Yuan W & Bers DM (2001). Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 88, 1159-1567.
84. 2+-exchanger overexpression on excitation-contraction coupling in adult rabbit ventricular myocytes. J Mol Cell Cardiol 34, 389-400.
85. Rasmussen RP, Minobe W & Bristow MR (1990). Calcium antagonist binding sites in failing and nonfailing human ventricular myocardium. Biochem Pharmacol 39, 691-696.
86. Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J Jr, Lefkowitz RJ & Koch WJ (1998). Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A 95, 7000-7005.
87. Sato Y, Kiriazis H, Yatani A, Schmidt AG, Hahn H, Ferguson DG, Sako H, Mitarai S, Honda R, Mesnard-Rouiller L, Frank KF, Beyermann B, Wu G, Fujimori K, Dorn GW II & Kranias EG (2001). Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem 276, 9392-9399.
88. 2+-ATPase. Circulation 101, 790-796.
89. Schmidt U, Hajjar RJ, Helm PA, Kim CS, Doye AA & Gwathmey JK (1998). Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol 30, 1929-1937.
90. 2+-ATPase activity and phosphorylation level of phospholamban. Am J Physiol 277, H474-480.
91. Schnepp B & Clark KR (2002). Highly purified recombinant adeno-associated virus vectors preparation and quantitation. Methods Mol Med 69, 427-443.
92. 2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92, 3220-3228.
93. 2+-sensitivity or myosin ATPase-activity of the contractile proteins. Basic Res Cardiol 95, 12-18.
94. 2+-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol 31, 479-491.
95. Shi CX, Hitt M, Ng P & Graham FL (2002). Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther 13, 211-224.
96. Stevenson LW (1998). Inotropic therapy for heart failure. N Engl J Med 339, 1848-1850.
97. Svensson EC, Marshall DJ, Woodard K, Lin H, Jiang F, Chu L & Leiden JM ( 1999). Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation 99, 201-205.
98. Szatkowski ML, Westfall MV, Gomez CA, Wahr PA, Michele DE, Dellorusso C, Turner II, Hong KE, Albayya FP & Metzger JM (2001). In vivo acceleration of heart relaxation performance by parvalbumin gene delivery. J Clin Invest 107, 191-198.
99. 2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J Clin Invest 90, 927-935.
100. Thuerauf DJ, Hoover H, Meller J, Hernandez J, Su L, Andrews C, Dillmann WH, McDonough PM & Glembotski, CC (2001). Sarco/endoplasmic reticulum calcium ATPase-2 expression is regulated by ATF6 during the endoplasmic reticulum stress response: intracellular signaling of calcium stress in a cardiac myocyte model system. J Biol Chem 276, 48309-48317.
101. Towbin JA & Bowles NE (2002). The failing heart. Nature 415, 227-233.
102. Wahr PA, Michele DE & Metzger JM (1999). Parvalbumin gene transfer corrects diastolic dysfunction in diseased cardiac myocytes. Proc Natl Acad Sci U S A 96, 11982-11985.
103. Watson DJ, Kobinger GP, Passini MA, Wilson JM & Wolfe JH (2002). Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, ebola, mokola, LCMV, or MuLV envelope proteins. Mol Ther 5, 528-537.
104. Wattanapitayakul SK & Bauer JA (2000). Recent developments in gene therapy for cardiac disease. Biomed Pharmacother 54, 487-504.
105. 2+ sparks, and local control of excitation-contraction coupling in normal heart muscle. Circ Res 85, 770-776.
106. 2+-ATPase isoform transcripts. Am J Physiol 269, C775-784.